NASDAQ:CYTK - Cytokinetics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$10.05 +0.48 (+5.02 %)
(As of 05/26/2019 04:00 PM ET)
Previous Close$10.05
Today's Range$9.62 - $10.38
52-Week Range$5.75 - $11.33
Volume770,976 shs
Average Volume555,114 shs
Market Capitalization$580.10 million
P/E RatioN/A
Dividend YieldN/A
Beta2.05
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, as well as in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274, a novel cardiac myosin inhibitor, which is in Phase I clinical trial for the potential treatment of hypertrophic cardiomyopathy; and AMG 594, a novel cardiac troponin activator that is in Phase I clinical trial. The company has strategic alliances with Amgen Inc. and Astellas Pharma Inc. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.

Receive CYTK News and Ratings via Email

Sign-up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CYTK
CUSIPN/A
Phone650-624-3000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$31.50 million
Book Value$0.06 per share

Profitability

Net Income$-106,290,000.00
Net Margins-303.70%

Miscellaneous

Employees130
Market Cap$580.10 million
Next Earnings Date7/25/2019 (Estimated)
OptionableOptionable

Cytokinetics (NASDAQ:CYTK) Frequently Asked Questions

What is Cytokinetics' stock symbol?

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

How were Cytokinetics' earnings last quarter?

Cytokinetics, Inc. (NASDAQ:CYTK) posted its earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.47) by $0.07. The biopharmaceutical company earned $8.46 million during the quarter, compared to the consensus estimate of $6.21 million. Cytokinetics had a negative return on equity of 269.27% and a negative net margin of 303.70%. View Cytokinetics' Earnings History.

When is Cytokinetics' next earnings date?

Cytokinetics is scheduled to release their next quarterly earnings announcement on Thursday, July 25th 2019. View Earnings Estimates for Cytokinetics.

What price target have analysts set for CYTK?

4 equities research analysts have issued 1-year price objectives for Cytokinetics' shares. Their forecasts range from $10.00 to $26.00. On average, they expect Cytokinetics' share price to reach $15.75 in the next twelve months. This suggests a possible upside of 56.7% from the stock's current price. View Analyst Price Targets for Cytokinetics.

What is the consensus analysts' recommendation for Cytokinetics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cytokinetics.

What are Wall Street analysts saying about Cytokinetics stock?

Here are some recent quotes from research analysts about Cytokinetics stock:
  • 1. According to Zacks Investment Research, "Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. " (5/14/2019)
  • 2. Cantor Fitzgerald analysts commented, ". We reiterate our OW rating and 12-month and raise our price target from $10 to $14 per share of CYTK primarily driven by increased visibility on the omecamtiv (ome’) programs with the initiation of the P3 METEORIC-HF study and removal of the FORTITUDE-ALS overhang. On Thursday AMC Cytokinetics reported 1Q19 revenue of $8.5M & cash of $177M. Our model projects current cash provides two years of runaway (through 2020), which should include readout of the METEORIC-HF studies." (5/10/2019)
  • 3. HC Wainwright analysts commented, "Valuation and potential impediments to achieving it. We reiterate our Buy rating and $26 target. We highlight that omecamtiv, partnered globally with Amgen, drives the lion’s share of our current valuation (>80%). Reldesemtiv (CK-107) represents the remainder of the contribution to our valuation (10.2% for SMA and 6.3% for ALS) with no contribution from the pipeline, especially CK-274, which is now clinical stage. Our price target is based on our clinical net present value (NPV) model." (5/6/2019)

Has Cytokinetics been receiving favorable news coverage?

Media coverage about CYTK stock has been trending somewhat negative on Sunday, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cytokinetics earned a media sentiment score of -1.8 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future.

Who are some of Cytokinetics' key competitors?

What other stocks do shareholders of Cytokinetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Amgen (amgn), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), TG Therapeutics (TGTX), TherapeuticsMD (TXMD), Geron (GERN) and Inovio Pharmaceuticals (INO).

Who are Cytokinetics' key executives?

Cytokinetics' management team includes the folowing people:
  • Mr. Robert I. Blum, CEO, Pres & Director (Age 55)
  • Mr. Ching W. Jaw, Sr. VP & CFO (Age 56)
  • Dr. Andrew A. Wolff, Sr. VP & Chief Medical Officer (Age 64)
  • Dr. Fady Ibraham Malik, Exec. VP of R&D (Age 55)
  • Dr. Bradley Paul Morgan, Sr. VP of Research & Non-Clinical Devel. (Age 59)

Who are Cytokinetics' major shareholders?

Cytokinetics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.01%), BVF Inc. IL (6.59%), Wasatch Advisors Inc. (5.76%), FMR LLC (3.34%), Geode Capital Management LLC (1.21%) and Pinnacle Associates Ltd. (1.08%). Company insiders that own Cytokinetics stock include Bradley Paul Morgan, Caryn Gordon Mcdowell, Fady Ibraham Malik, Robert I Blum and Santo J Costa. View Institutional Ownership Trends for Cytokinetics.

Which major investors are selling Cytokinetics stock?

CYTK stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Dimensional Fund Advisors LP, Citigroup Inc., Morgan Stanley, Ironwood Investment Management LLC, ClariVest Asset Management LLC, California State Teachers Retirement System and Principal Financial Group Inc.. Company insiders that have sold Cytokinetics company stock in the last year include Fady Ibraham Malik and Robert I Blum. View Insider Buying and Selling for Cytokinetics.

Which major investors are buying Cytokinetics stock?

CYTK stock was acquired by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Renaissance Technologies LLC, BlackRock Inc., Oxford Asset Management LLP, Geode Capital Management LLC, Jacobs Levy Equity Management Inc., FMR LLC and Goldman Sachs Group Inc.. View Insider Buying and Selling for Cytokinetics.

How do I buy shares of Cytokinetics?

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cytokinetics' stock price today?

One share of CYTK stock can currently be purchased for approximately $10.05.

How big of a company is Cytokinetics?

Cytokinetics has a market capitalization of $580.10 million and generates $31.50 million in revenue each year. The biopharmaceutical company earns $-106,290,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. Cytokinetics employs 130 workers across the globe.

What is Cytokinetics' official website?

The official website for Cytokinetics is http://www.cytokinetics.com/.

How can I contact Cytokinetics?

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]


MarketBeat Community Rating for Cytokinetics (NASDAQ CYTK)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  591 (Vote Outperform)
Underperform Votes:  223 (Vote Underperform)
Total Votes:  814
MarketBeat's community ratings are surveys of what our community members think about Cytokinetics and other stocks. Vote "Outperform" if you believe CYTK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/26/2019 by MarketBeat.com Staff

Featured Article: Dividend Yield

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel